Impact of IL-28B SNPs on control of hepatitis C virus infection: a genome-wide association study.
Imazeki
Fumio
F
Yokosuka
Osamu
O
Omata
Masao
M
D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D055106:Genome-Wide Association Study; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000517:prevention & control / Q000821:virology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D007378:Interleukins / Q000235:genetics* / Q000378:metabolism; D011092:Polyethylene Glycols / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome; D000095022:Interferon Lambda
D000998:Antiviral Agents; D007372:Interferons; D007378:Interleukins; D011092:Polyethylene Glycols; D012254:Ribavirin; C000624353:interferon-lambda, human; D000095022:Interferon Lambda